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Background:
sites of the nociceptive pathway. Fixed-dose combination analgesics facilitate a reduction in dose of individual components, 
tolerability of two widely prescribed combination analgesics, Stilpane® (paracetamol/codeine/meprobamate) and Tramacet® 
(paracetamol/tramadol). 
Methods: A prospective randomised parallel group phase IV clinical trial was conducted in 100 patients experiencing moderate 
to severe pain after third molar extraction at the Oral and Dental Hospital, University of Pretoria. Pain intensity and pain relief 
and Total Pain Relief (TOTPAR) were calculated according to standard methods. Beck Anxiety Questionnaire assessed anxiety. 
Results:
Conclusions:
well-tolerated combination analgesics in patients experiencing moderate to severe acute pain.
Keywords: acute pain, anxiolytic, codeine, combination analgesics, meprobamate, paracetamol, Stilpane®, Tramacet®, tramadol
Introduction
Acute pain is disabling and common, and while it may be inevitable, 
1 
Aggressive control of acute pain may also reduce the risk of 
developing chronic or even lifelong pain.2 Successful treatment of 
moderate to severe acute pain often necessitates several analgesics 
the cause of the pain as well as other patient and external factors, 
a traditional stepwise approach includes commencing treatment 
(NSAID) and thereafter, co-prescribing a weak opioid such as 
codeine or tramadol.3 This rational practice facilitates additive or 
the use of the more potent opioids.4,5 The strong opioid-sparing 
constipation, urinary retention, respiratory depression and 
sedation, which are important factors particularly when 
considering pain associated with ambulatory surgery and the 
increasing need to facilitate an earlier hospital discharge.5
potential advantages over monotherapy which include a reduction 
in dose of each of the components, theoretically resulting in 
combination analgesics may also be invaluable in promoting 
compliance.6 For instance, Stilpane®, a combination analgesic 
widely prescribed in South Africa contains relatively small doses of 
respectively in acute pain management.7,8 Low-dose meprobamate 
9 Pain is often 
accompanied by anxiety, and in the past it was therefore considered 
its anxiolytic properties.9 Yet it appears that meprobamate also 
possesses intrinsic analgesic properties, which may further 
10 Another 
popular South African combination analgesic, Tramacet®, 
interaction allows for a substantial reduction in the usual individual 
dose.11 Analgesic superiority has been demonstrated for this 
combination compared to its individual components.11 Of note is 
which are associated with gastric ulceration and haemorrhage, and 
possibly a delay in post-surgical bone healing.12 Opioids are 
preferred to NSAIDs in this context as well as in patients with renal 
impairment, bleeding disorders, on anticoagulant therapy or who 
have other contraindications including pregnancy and allergies.
severe pain and are often used interchangeably in South 
Africa.13–15 However, their mechanisms of action are somewhat 
Stilpane® and Tramacet® in an acute pain model. Removal of 
wisdom teeth (the four third molars) is usually accompanied by 
16 
Understandably the procedure may also cause considerable 
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A prospective single-blind randomised parallel group single 
centre phase IV clinical trial was conducted to compare the 
Tramacet® using a validated acute third molar extraction pain 
model.18
The study was approved by the University of Pretoria Research 
Ethics Committee (236/2112) and was registered with NHREC 
(DOH-27–0313-4234). The Medicines Control Council was also 
Patients were recruited from February 2013–November 2013.
Study population
One hundred eligible patients presenting to the Oral and Dental 
Hospital, University of Pretoria, generally in good health according 
to the American Society of Anaesthesiologists’ Scale (Stage I or II), 
outpatient extraction of three or four impacted molars, two of 
which were mandibular thus requiring bone removal, with an 
and having given written informed consent, were selected to 
participate in the study. Patients who were pregnant or lactating, 
illiterate or diagnosed with psychotic or bipolar disorders, those 
whose intake of alcohol exceeded 25 units a week, those with 
serious cardiovascular disease, brain injury or seizure disorders, 
and those on concurrent opioids, cocaine, stimulants, 
antidepressants, antipsychotics or anxiolytic medication, were 
excluded from the study.
Patients who scored 2 (moderate) or 3 (severe) on the 4-point 
Likert scale for pain intensity19
pain visual analogue scale,20 within 2 h post-surgery, were 
randomised in block sizes of ten to one of the two treatment 
groups where they received either two Stilpane® capsules or two 
Tramacet® tablets six hourly. Patients were unaware of the 
treatment received and identical medication bottles were coded 
and packaged with study medication according to the 
randomisation sequence in order to maintain the blind. Rescue 
common to both preparations, in order to limit the confounding 
potential of additional drug–drug interactions.
In accordance with the Declaration of Helsinki, the European 
Union Clinical Trials Directive, the Food and Drug Administration 
and other Good Clinical Practice regulations, patients had the 
right to withdraw from the study without prejudicing their 
subsequent medical care.
Patients reported pain intensity on the 4-point Likert Scale, where 
0 represented no pain, 1: mild pain, 2: moderate pain and 3: 
severe pain, as soon as they were coherent post-surgery.19 Patients 
also recorded their pain intensity on a visual analogue pain scale 
20
(PAR) was also measured at these time points using the 5-point 
Likert Scale where 0 denoted none, 1: a little, 2: some, 3: a lot and 
4: complete.21
time to perceptible pain relief as well as meaningful pain relief 
after the administration of the initial dose of analgesic.
The Beck Anxiety Questionnaire which measures cognitive and 
somatic components of anxiety was used to assess patients’ 
of 0–16 represented mild, 17–30: moderate, and 31 and above: 
severe anxiety.22
Tolerability and safety
Vital signs including blood pressure, body weight, height, respiration 
and heart rates were recorded before and immediately after surgery, 
Any adverse changes in a patient’s medical condition was 
recorded as an adverse event. Patients received a diary card to 
record adverse events at home and the investigator categorised 
these by their relationship to study medication, intensity and 
seriousness. The outcome of the event was also recorded. Serious 
Adverse Events were reported to the University of Pretoria’s Ethics 
Statistical analyses
A sample size of at least 26 patients per group was required for a 
(ITT) and per-protocol (PP) populations, while safety analyses 
included randomised patients who took at least one dose of 
study treatment. Continuous data was summarised using 
descriptive statistics such as number of observations (n), mean, 
standard deviation (SD), median, minimum (min) and 
maximum(max). Categorical data was presented as absolute 
numbers (n) and percentage (%).
(PID) between baseline and scheduled visits, and hourly pain 
relief (PAR) at each time point. The Summed Pain Intensity 
(SPRID) and Total Pain Relief (TOTPAR) were calculated according 
to standard methods. Analysis of covariance (ANCOVA) was used 
to analyse SPID and SPRID, the VAS and the Beck Anxiety Scores. 
Analysis of variance (ANOVA) was used to analyse TOTPAR and 
included treatment arms as factors. Shapiro–Wilk test was used 
with corresponding p
Results
Demographic and other baseline characteristics
and 48 in the Tramacet® group) enrolled in and completed the 
study. All were included in the safety and ITT populations 
(Figure 1). The study population comprised more women than 
groups was similar (Table 1).
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moderate to severe acute pain associated with third molar 
(Table 2) This was corroborated by the results of the pain intensity 
assessment by VAS (Table 3) as well as total pain relief (TOTPAR) 
(Table 4), sum of hourly pain relief and hourly pain intensity 
5
groups. Furthermore, analyses of secondary variables including 
perceptible pain relief and time taken for meaningful pain relief 
were comparable between the two groups (data not shown).
good. At this time, 2% in both groups thought it was poor, 4% in 
Figure 1: 
Table 1: Demographic characteristics (gender and race)
Variable Categories Stilpane® Capsules N = 52 Tramacet® Tablet N = 48 Overall N = 100
n (%)
Gender Male 17 (32.7) 20 (41.7) 37 (37.0)
Female 35 (67.3) 28 (58.3) 63 (63.0)
Race Caucasian 30 (57.7) 22 (45.8) 52 (52.0)
Black 19 (36.5) 24 (50.0) 43 (43.0)
Asian 0 1 (2.1) 1 (1.0)
Other 3 (5.8) 1 (2.1) 4 (4.0)
Table 2:
Visit Stilpane® capsules 
N = 52 
Mean (SD)
Tramacet® tablet 





−3.46 (1.64) −3.05 (2.12) −0.13 (−0.76, 0.51) 0.6878
−6.58 (14.10) −3.51 (20.05) −3.04 (−9.97, 3.90) 0.3873
Visit 3 (48 ± 24 h) −86.54 (36.36) −90.14 (39.65) 7.45 (−6.74, 21.65) 0.3001
−252.69 (86.99) −250.14 (91.57) 9.56 (−21.58, 40.70) 0.5436
a
Allocated to Stilpane® (n = 52)
Received allocated intervention (n = 52)
Did not receive allocated intervention (n = 0)





Assessed for eligibility (n = 103)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Allocated to Tramacel® (n = 48)
Received allocated intervention (n = 48)
Did not receive allocated intervention (n = 0)
Excluded (n = 3)
Not meeting inclusion criteria (n = 3)
ITT Analysis (n = 52)
Excluded from analysis (n = 0)
ITT Analysis (n = 48)
Excluded from analysis (n = 0
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
 Consolidated Standards of Reporting Trials (CONSORT) ow diagram
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Tolerability and safety
signs and physical examinations were within normal ranges. The 
most common treatment emergent events were nausea (Stilpane® 
9.6 %, Tramacet® 12.5%), vomiting (Stilpane® 5.8 %, Tramacet® 
6.3%), somnolence (Stilpane® 15.4%, Tramacet 14.6%), dizziness 
(Stilpane® 1.9 %, Tramacet 6.3%), headache (Stilpane® 1.9 %, 
Tramacet® 2.1%), insomnia (Stilpane® 1.9%, Tramacet® 2.1%), 
pruritus (Stilpane® 5.8 %, Tramacet® 2.1%) and rash (Stilpane® 0 %, 
Tramacet® 4.2%). No patients discontinued treatment due to 
Discussion
severe pain. This study compared the analgesic and anxiolytic 
extraction, a procedure commonly associated with substantial pain 
ensure that patients underwent similar degrees of surgery. The 
maximum achievable score of 16 took cognisance of whether teeth 
were erupted and whether impaction involved soft tissue, partial 
bone, complete bone or unusual impaction such as horizontal/
inverted or posterior/anterior.18 All patients required bone removal 
for two mandibular impacted molars. Not surprisingly, all enrolled 
patients experienced moderate to severe post-operative pain and 
were therefore eligible for inclusion in the study.
the Stilpane® group and 13% in the Tramacet® group fair, 33% in 
the Stilpane® group and 38% in the Tramacet® group good, and 
22% in the Stilpane® group and 10% in the Tramacet® group 
In both treatment groups, approximately 70% of patients 
achieved perceptible pain relief and 35% of patients achieved 
treatments (data not shown).
Anxiety was assessed prior to and post-surgery, and thereafter, at 
or Tramacet®. The shift in anxiety levels from baseline is outlined 
in Table 6. More than 90% of patients in both treatment arms 
dose which was largely sustained for the duration of the study 
period. At 48 h, however, two patients in the Tramacet® group 
developed moderate anxiety, one of whom returned to a state of 
Tramacet® group who initially experienced moderate anxiety, 
group experienced moderate anxiety throughout the study 
treatment arms.
Table 3: Visual analogue pain scale (ITT population)









−55.32 (24.21) −52.38 (23.28) −0.57 (−8.92, 7.78) 0.8931
−61.25 (27.67) −60.76 (23.05) 1.34 (−8.44, 11.12) 0.7862
Visit 3 (48 ± 24 h) −68.02 (23.74) −71.21 (15.95) 5.58 (−1.01, 12.16) 0.0960
−73.50 (20.59) −70.63 (20.84) −0.63 (−7.58, 6.32) 0.8572
a
Table 4: Assessment of total pain relief (TOTPAR) (ITT population)
Visit Stilpane® Capsules 
N = 52 
Mean (SD)
Tramacet® Tablet 





5.58 (1.58) 5.54 (1.93) 0.04 (−0.66, 0.73) 0.9204
15.52 (13.59) 17.88 (19.22) −2.36 (−8.92, 4.21) 0.4782
Visit 3 (48 ± 24 h) 145.56 (44.06) 157.0 (30.83) −11.44 (−26.65, 3.77) 0.1387
413.25 (96.35) 430.33 (80.34) −17.08 (−52.45, 18.28) 0.3401
a
Table 5:
Visit Stilpane® capsules 
N = 52 
Mean (SD)
Tramacet® tablet 





2.45 (1.72) 2.82 (2.06) 0.01 (−0.50, 0.52) 0.9656
9.28 (27.02) 14.70 (38.69) −5.77 (−19.12, 7.57) 0.3925
Visit 3 (48 ± 24 h) 59.36 (43.10) 67.20 (43.83) −2.70 (−18.46, 13.07) 0.7348
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anxiety score of 0–16 is interpreted as mild anxiety. It is thus 
conceivable that these patients experienced no anxiety at all. 
Furthermore, it is likely that whatever procedure-related anxiety 
was present, continued to diminish due to adequate analgesia as 
well as to the healing passage of time. Studies assessing the 
more informative.
Although there appeared to be a greater trend for pruritus in 
Stilpane® treated patients and dizziness and rash in patients who 
treatment groups. It should be noted that nausea and vomiting 
may add to the subjective experience of pain, and that these 
adverse events were reported in approximately 5–10% of patients 
required, underscoring the advantage of reducing the dose of 
individual components in combination analgesics.
Assessing physical dependence and/or addiction potential of low 
dose, short term use of tramadol, codeine or meprobamate was 
beyond the scope of this study.
Conclusion 
This study demonstrated that despite their distinctive 
compositions and mechanisms of action, Stilpane® and Tramacet® 
eligible patients experiencing moderate to severe acute pain. 
patients with coexisting high levels of acute anxiety or co-morbid 
medical conditions. Meanwhile, the interchangeable use of 
Acknowledgements – The authors wish to acknowledge Prof FJ 
Jacobs, Dr GJ Roode, Dr S Naidoo, Miss M. Kotzè; Miss TL Venter 
their generous funding.
writing this paper.
Stilpane® and Tramacet® contain similar doses of paracetamol, 
in Stilpane®, and tramadol present in Tramacet® are both pure 
23 Tramadol also 
increases synaptic serotonin and noradrenaline levels, thereby 
acting on an additional site along the nociceptive pathway. 
Nonetheless, per milligram, codeine and tramadol are considered 
to have similar opioid analgesic equivalence.24 The analgesic 
Tramacet® in alleviating the moderate to severe acute pain 
contrasted with 10% of patients in the Tramacet® group.
component, meprobamate. Although it harbours analgesic 
properties, it is unlikely that low dose meprobamate possesses an 
mechanism. This notion is supported by acute25 and chronic8 pain 
together, it appears that meprobamate is a crucial component of 
the ultra-low dose codeine combination analgesic.
Meprobamate’s mechanism of anxiolytic action is related to its 
A receptors.
9,10 
Therefore it was anticipated that Stilpane® would achieve a far 
preoperative anxiety, postoperative anxiety was reduced 
or Tramacet®, ostensibly because the anticipatory fear related to 
severity of anxiety experienced by most patients in each 
treatment group prior to the administration of the combination 
analgesics was mild, which made assessing any subtle changes 
Table 6: Shift in anxiety level (ITT population)
Baseline
Stilpane® (N = 52) n (%) Tramacet® (N = 48) n (%)
Mild Moderate Severe Mild Moderate Severe
Mild 49 (94.2) 3 (5.8) 0 46 (95.8) 2 (4.2) 0
Moderate 0 0 0 0 0 0
Severe 0 0 0 0 0 0
Visit 3 (48 ± 24 h)
Mild 49 (94.2) 3 (5.8) 0 44 (91.7) 1 (2.1) 0
Moderate 0 0 0 2 (4.2) 1 (2.1) 0
Severe 0 0 0 0 0 0
Mild 49 (94.2) 3 (5.8) 0 45 (93.8) 1 (2.1) 0
Moderate 0 0 0 1 (2.1) 1 (2.1) 0
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